Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 3, Number 3—September 1997
Perspective

Resistance, Remission, and Qualitative Differences in HIV Chemotherapy

Denise E. Kirschner*Comments to Author  and G.F. Webb
Author affiliations: *University of Michigan Medical School, Ann Arbor, Michigan, USA; and †Vanderbilt University, Nashville, Tennessee, USA

Main Article

Figure 1

A simulation of HIV dynamics for the model (A.1) - (A.3) with T(0) = 600/mm3 and Vs(0) = 10/mm3. The curves correspond to data in (11). The set-point of the virus is in the middle range (15) and corresponds to a typical disease progression of about 9 years. The contribution to the plasma virus from the external lymphoid compartment is more than 90%, as may be computed from equation (A.3). The curves T(t) and Vs(t) are approximately inversely proportional, as may be seen from equation (A.3) (the

Figure 1. A simulation of HIV dynamics for the model (A.1) - (A.3) with T(0) = 600/mm3 and Vs(0) = 10/mm3. The curves correspond to data in (11). The set-point of the virus is in the middle range (15) and corresponds to a typical disease progression of about 9 years. The contribution to the plasma virus from the external lymphoid compartment is more than 90%, as may be computed from equation (A.3). The curves T(t) and Vs(t) are approximately inversely proportional, as may be seen from equation (A.3) (the inverse proportionality is specific to a given set-point). In c,d, a simulation of a combined drug treatment corresponds to data in (9). The treatment begins with the uninfected CD4+ T-cell count at 200/mm3, the infected CD4+ T-cell count at 9.5/mm3, and the virus level at 34/mm3 (these values are obtained from the simulation in a, b at 7.9 years). In d, the heavy line is the total virus population, the thin line is the wild-type virus population, and the dashed line is the drug-resistant virus population. Complete replacement of wild-type virus by resistant virus occurs by week 5. The treatment parameters are c1=.5, c2=.025, c3=.15, and the resistance mutation parameter is q=10-7.

Main Article

References
  1. Ho  DD, Neumann  AU, Perelson  AS, Chen  W, Leonard  JM, Markowitz  M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:1236. DOIPubMedGoogle Scholar
  2. Wei  X, Ghosh  SK, Taylor  ME, Johnson  VA, Emini  EA, Deutsch  P, Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:11722. DOIPubMedGoogle Scholar
  3. Perelson  AS, Neumann  AU, Markowitz  M, Leonard  JM, Ho  D. HIV-1 Dynamics in vivo: clearance rate, infected cell lifespan, and viral generation time. Science. 1996;271:15826. DOIPubMedGoogle Scholar
  4. Piatak  M, Saag  MS, Yang  LC, Clark  SJ, Kappes  JC, Luk  KC, High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993;259:174954. DOIPubMedGoogle Scholar
  5. Richman  DD. HIV therapeutics. Science. 1996;272:18867. DOIPubMedGoogle Scholar
  6. Coffin  JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science. 1995;267:4839. DOIPubMedGoogle Scholar
  7. Stephenson  J. New anti-HIV drugs and treatment strategies buoy AIDS researchers. JAMA. 1996;275:57980. DOIPubMedGoogle Scholar
  8. Carpenter  CJ, Fischl  MA, Hammer  SM, Hirsch  MS, Jacobsen  DM, Katzenstein  DA, Antiretroviral therapy for HIV infection. JAMA. 1996;276:14654. DOIPubMedGoogle Scholar
  9. Collier  AC, Coombs  RW, Schoenfeld  DA, Bassett  RL, Timpone  J, Baruch  A, Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:10117. DOIPubMedGoogle Scholar
  10. Cohen  J. Science. 1996;273:302.AIDS Conference. Chemokines share center stage with drug therapies. PubMedGoogle Scholar
  11. Pennisi  E, Cohen  J. Eradicating HIV from a patient: not just a dream? Science. 1996;272:1884. DOIPubMedGoogle Scholar
  12. Grody  WW, Fligiel  S, Naeim  F. Thymus involution in the acquired immunodeficiency syndrome. Am J Clin Pathol. 1985;84:8595.PubMedGoogle Scholar
  13. Philips  AN, Sabin  CA, Mocroft  A, Janossy  G. Antiviral therapy. Nature. 1995;375:195. DOIGoogle Scholar
  14. Embretson  J, Zupancic  M, Ribas  JL, Burke  RA, Racz  P, Tenner-Racz  K, Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:35962. DOIPubMedGoogle Scholar
  15. Ho  D. Viral counts in HIV infection. Science. 1996;272:11245. DOIPubMedGoogle Scholar
  16. Mellors  JW, Rinaldo  CR, Gupta  P, White  RM, Todd  JA, Kingsely  LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:116770. DOIPubMedGoogle Scholar
  17. Pantaleo  G, Graziosi  C, Demarest  JF, Butini  L, Montroni  M, Fox  CH, HIV infection is active and progressive in lymphoid during the clinically latent stage of disease. Nature. 1996;362:3558. DOIGoogle Scholar
  18. Lafeuillade  A, Poggi  C, Profizi  N, Tamalet  C, Costes  O. Human immunodeficiency virus type I kinetics in lymph nodes compared with plasma. J Infect Dis. 1996;174:4047.PubMedGoogle Scholar
  19. McLean  A, Nowak  M. Competition between AZT sensitive and AZT resistant strains of HIV. AIDS. 1992;6:719. DOIPubMedGoogle Scholar
  20. Fischl  MA, Richmann  DD, Hansen  N, Collier  AC, Carey  JT, Para  MF, The safety and efficiency of AZT in the treatment of subjects with mildly symptomatic HIV type 1. Ann Intern Med. 1990;112:72737.PubMedGoogle Scholar
  21. Graham  NMH, Zeger  SL, Park  LP, Vermund  SH, Detels  R, Rinaldo  CR, The effects on survival of early treatment of HIV infection. N Engl J Med. 1992;326:103742.PubMedGoogle Scholar
  22. Hamilton  JD, Hartigan  PM, Simberkoff  MS, Day  PL, Diamond  GR, Dickinson  GM, A controlled trial of early vs late treatment with AZT in symptomatic HIV infection. N Engl J Med. 1992;326:43743.PubMedGoogle Scholar
  23. Montaner  JSG, Singer  J, Schechter  MT. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT trial. AIDS. 1993;7:18995. DOIPubMedGoogle Scholar
  24. Kirschner  DE, Webb  GF. A model for treatment strategy in the chemotherapy of AIDS. Bull Math Biol. 1996;58:36791. DOIGoogle Scholar
  25. Tough  DF, Sprent  J. Lifespan of lymphocytes. Immunol Res. 1995;14:114. DOIPubMedGoogle Scholar
  26. Perelson  AS, Kirschner  DE, DeBoer  R. The dynamics of HIV infection of CD4+ T cells. Math Biosci. 1993;114:81125. DOIPubMedGoogle Scholar
  27. Kirschner  DE, Webb  GF. Effects of drug resistance on monotherapy treatment of HIV infection. Bull Math Biol 1997.
  28. Kirschner  DE, Webb  GF. A mathematical model of combined drug therapy of HIV infection. J Theor Med. 1997. In press.

Main Article

Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external